FDA’s eCTD hierarchy includes a Study report body heading mapped to ICH E3 sections 1 and 3 through 15, separate from the synopsis and specified appendix or supporting-document headings. This page is scoped to FDA eCTD placement and naming; other submission systems or regional implementations can differ.
ReviewedEvidence2 sourcesSectionWriting & Style
Quick answer
Use the Study report body heading for the main CSR body material identified by the FDA eCTD hierarchy, keeping separately tagged synopsis and supporting materials in their own headings.
Key details
Core IssueFDA’s eCTD hierarchy includes a Study report body heading mapped to ICH E3 sections 1 and 3 through 15, separate from the synopsis and specified appendix or supporting-document headings.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This page is scoped to FDA eCTD placement and naming; other submission systems or regional implementations can differ.
Further guidance
Content
Treat this as an electronic-submission organization rule: it does not redefine the substantive content of ICH E3 sections or collapse appendix materials into the report body.
Purpose
Use the Study report body heading for the main CSR body material identified by the FDA eCTD hierarchy, keeping separately tagged synopsis and supporting materials in their own headings.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
FDA’s current eCTD table-of-contents hierarchy places clinical study reports and related information under Module 5 section 5.3 and provides structured headings for the report and associated materials. This guide describes FDA eCTD organization, not the substantive clinical content required for every study or every jurisdiction.
FDA’s June 2026 Study Data Technical Conformance Guide recommends an Analysis Data Reviewer’s Guide (ADRG) as a single orientation point for analysis datasets and states that the clinical-study ADRG belongs with the analysis data in Module 5. This is FDA submission guidance for analysis data and should not be generalized as a universal document requirement outside the applicable regulatory context.
FDA’s Module 5 hierarchy includes analysis-dataset headings, and the current Study Data Technical Conformance Guide provides the technical framework for standardized analysis data submitted for clinical studies. This page concerns FDA study-data submission organization; it is not a substitute for the current Data Standards Catalog or study-specific review-division advice.
FDA’s Module 5 hierarchy provides data-tabulation headings, including standardized clinical tabulation data, while the current Study Data Technical Conformance Guide addresses supported study-data submission standards and organization. This is FDA electronic-submission guidance and does not by itself determine which dataset standard is required for every study; current catalog and conformance requirements still govern.
FDA’s June 2026 study-data folder table uses a misc subfolder for miscellaneous datasets that do not qualify as analysis, profile, or tabulation datasets and notes that this folder was formerly named listings. This is current FDA study-data directory guidance. The historical listings folder name is a boundary note, not evidence for a separate present-day data-listing dataset definition.
